Asahi Kasei (AHKSF)

Wednesday

6:43 PM

ThesisThe recent growth in the healthcare division and strategic investments in sustainable materials are enhancing Asahi Kasei's growth outlook, driving investor sentiment positively.

Revenue Outlook

Metric	FY2026	FY2027E	FY2028E
Revenue	$3.09T	$3.45T	$3.55T
Rev. Growth	+1.9%	+11.6%	+2.7%
EPS	$118.24	$133.22	$146.61
EPS Growth	+20.7%	+12.7%	+10.1%
P/E (fwd)	0.1×	0.1×	0.1×

★ Analysts see FY2027 revenue reaching $3.45T — +11.6% growth in a single year.

The Bull Case for Growth

01Asahi Kasei's healthcare division is expected to see a 25% increase in revenue driven by new biopharmaceutical contracts.
02The company is investing $300 million in R&D for sustainable materials, positioning itself ahead of regulatory changes.
03Recent partnerships with electric vehicle manufacturers could lead to a 15% increase in performance materials sales.
04Sustainability in chemical production
05Growth in electric vehicle materials
06Demand for automotive materials, particularly in electric vehicles
07Healthcare product sales growth, especially in biopharmaceuticals
08Fluctuations in raw material prices, particularly petrochemicals

FY2026 Snapshot

Revenue: $3.09T
Rev. Growth: +1.9%
Gross Margin: 32.8%
Op. Margin: 7.5%
Net Margin: 5.2%
Net Income: $159.8B
NI Growth: +18.4%
EPS: $118.24
1Y Return: +42.2%

My Notes

"Our commitment to innovation in healthcare and sustainability is paving the way for significant growth opportunities."
Moat: Asahi Kasei's strong brand reputation and diversified product portfolio provide a durable competitive advantage.
value - Investors may be drawn to Asahi Kasei's solid fundamentals and attractive valuation metrics, such as a price-to-sales ratio of 0.8x.
Rising interest rates can increase financing costs for capital expenditures, impacting profitability and potentially slowing down expansion…
Watch on earnings: WTI Crude Oil Price (DCOILWTICO), Healthcare segment revenue growth, Operating cash flow margin.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $3.45T to $3.55T as asahi kasei's healthcare division is expected to see a 25% increase in revenue driven by new biopharmaceutical contracts.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.